Analysts expect Teladoc Inc (NYSE:TDOC) to report $107.79 million in sales for the current quarter, according to Zacks Investment Research. Eleven analysts have made estimates for Teladoc’s earnings, with the lowest sales estimate coming in at $107.00 million and the highest estimate coming in at $111.20 million. Teladoc reported sales of $68.65 million during the same quarter last year, which suggests a positive year-over-year growth rate of 57%. The company is scheduled to announce its next quarterly earnings report on Wednesday, November 7th.

On average, analysts expect that Teladoc will report full year sales of $407.92 million for the current fiscal year, with estimates ranging from $406.57 million to $409.80 million. For the next fiscal year, analysts anticipate that the company will report sales of $541.54 million per share, with estimates ranging from $531.04 million to $556.00 million. Zacks’ sales calculations are a mean average based on a survey of research analysts that follow Teladoc.

Teladoc (NYSE:TDOC) last issued its earnings results on Wednesday, August 1st. The health services provider reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.01. Teladoc had a negative return on equity of 19.10% and a negative net margin of 37.78%. The business had revenue of $94.60 million during the quarter, compared to the consensus estimate of $91.56 million. During the same quarter last year, the company earned ($0.28) EPS. The firm’s revenue was up 112.1% compared to the same quarter last year.

TDOC has been the topic of several recent analyst reports. Piper Jaffray Companies raised their price target on Teladoc to $46.00 and gave the company an “overweight” rating in a report on Monday, June 4th. Craig Hallum raised Teladoc from a “hold” rating to a “buy” rating in a report on Tuesday, June 5th. JPMorgan Chase & Co. raised their price target on Teladoc to $58.00 and gave the company an “overweight” rating in a report on Tuesday, June 5th. Canaccord Genuity raised their price target on Teladoc from $47.00 to $63.00 and gave the company a “buy” rating in a report on Tuesday, June 5th. Finally, SunTrust Banks raised their price target on Teladoc from $48.00 to $63.00 and gave the company a “buy” rating in a report on Tuesday, June 5th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $65.10.

In other news, President Peter A. Mcclennen sold 91,072 shares of Teladoc stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $65.84, for a total value of $5,996,180.48. Following the sale, the president now directly owns 61,660 shares in the company, valued at approximately $4,059,694.40. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Jason N. Gorevic sold 25,000 shares of Teladoc stock in a transaction that occurred on Monday, July 16th. The stock was sold at an average price of $66.11, for a total value of $1,652,750.00. Following the completion of the sale, the chief executive officer now owns 586,184 shares in the company, valued at $38,752,624.24. The disclosure for this sale can be found here. Over the last three months, insiders have sold 242,497 shares of company stock worth $16,108,269. 3.95% of the stock is currently owned by insiders.

Hedge funds have recently modified their holdings of the company. Bank of America Corp DE raised its stake in Teladoc by 82.8% during the second quarter. Bank of America Corp DE now owns 1,883,185 shares of the health services provider’s stock valued at $109,318,000 after buying an additional 853,076 shares during the last quarter. Summit Partners L P purchased a new position in shares of Teladoc in the second quarter worth $37,772,000. Westwood Management Corp IL raised its stake in shares of Teladoc by 1,342.6% in the second quarter. Westwood Management Corp IL now owns 585,700 shares of the health services provider’s stock worth $34,000,000 after purchasing an additional 545,100 shares during the last quarter. Bellevue Group AG raised its stake in shares of Teladoc by 997.2% in the first quarter. Bellevue Group AG now owns 515,694 shares of the health services provider’s stock worth $20,782,000 after purchasing an additional 468,694 shares during the last quarter. Finally, BlackRock Inc. raised its stake in shares of Teladoc by 9.0% in the second quarter. BlackRock Inc. now owns 5,318,850 shares of the health services provider’s stock worth $308,759,000 after purchasing an additional 437,136 shares during the last quarter.

NYSE TDOC traded down $3.35 during trading hours on Friday, hitting $73.95. The company had a trading volume of 69,178 shares, compared to its average volume of 1,118,675. Teladoc has a 52 week low of $27.30 and a 52 week high of $79.64. The company has a quick ratio of 3.14, a current ratio of 3.14 and a debt-to-equity ratio of 0.58. The company has a market cap of $5.35 billion, a P/E ratio of -46.18 and a beta of 0.58.

Teladoc Company Profile

Teladoc, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Featured Story: Risk Tolerance

Get a free copy of the Zacks research report on Teladoc (TDOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Teladoc (NYSE:TDOC)

Receive News & Ratings for Teladoc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc and related companies with MarketBeat.com's FREE daily email newsletter.